Antibody blocking of checkpoint inhibitors, with most focus on the PD-1/PDL-1 pathway, can increase CD8+ T cell function and, remarkably, in some cancer patients has afforded complete clinical response (190). The gene discussed is CD8A; the disease is cancer.